REMEGEN (09995) announced its interim results, achieving a net profit of approximately 4.662 billion yuan, turning from loss to profit year-on-year.
Rongchang Biotech (09995) announced its mid-year results for 2026, with product sales, R&D services, and licensing revenues totaling approximately 5.85 billion yuan, a year-on-year increase of 435.74%; R&D expenditure was approximately 414 million yuan, a year-on-year decrease of 36%; and profit for the period was approximately 4.662 billion yuan, marking a turnaround from loss to profit compared to the previous year.
REMEGEN (09995) announced its interim results for 2026, with product sales, R&D services, and licensing revenues amounting to approximately 5.85 billion yuan, a year-on-year increase of 435.74%; R&D expenditure was about 414 million yuan, a year-on-year decrease of 36%; the profit for the period was approximately 4.662 billion yuan, achieving a turnaround from losses to profits year-on-year.
The announcement stated that the increase in revenue was mainly due to the strong sales growth of the companys self-developed immunological commercial product Taitasib and the antineoplastic commercial product Vidutimab. During the reporting period, the company signed an exclusive licensing agreement with AbbVie for RC148, granting AbbVie exclusive rights for the development, production, and commercialization of RC148 outside Greater China, resulting in a significant increase in technology licensing revenue.
Related Articles
US Stock Market Move | The core executives have stepped in to increase their holdings as the decline in Alibaba Group Holding Limited Sponsored ADR (BABA.US) has narrowed to 0.23%.
CNGR Advanced Material (02579) announced its mid-term results, with a profit attributable to the owners of the parent company of approximately 1.3114 billion yuan, an increase of about 78.4% year-on-year.
JIAXIN INTL RES(03858) subsidiary ZV has entered into a construction contract for the Bakuta mining project with CCECC Kazakhstan Branch.
US Stock Market Move | The core executives have stepped in to increase their holdings as the decline in Alibaba Group Holding Limited Sponsored ADR (BABA.US) has narrowed to 0.23%.
CNGR Advanced Material (02579) announced its mid-term results, with a profit attributable to the owners of the parent company of approximately 1.3114 billion yuan, an increase of about 78.4% year-on-year.
JIAXIN INTL RES(03858) subsidiary ZV has entered into a construction contract for the Bakuta mining project with CCECC Kazakhstan Branch.
RECOMMEND
